21 March 2016 - Bach and colleagues’ article is particularly relevant because cancer drug expenditure is of major concern.

Increasing the range of vial strengths is one way to contain spending. Unfortunately vial sharing is not always feasible. In Australia, many cancer centres outsource cancer drug manufacturing to accredited commercial suppliers.

For more details, go to: http://www.bmj.com/content/352/bmj.i1551?etoc=